Found 8 articles for: "Safety"

Safety and Effectiveness of Synchronized Monopolar Radiofrequency and HIFES in Patients Injected With Botulinum Toxin

November 2024 | Volume 23 | Issue 11 | Original Article | 937 | Copyright © November 2024

A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia

April 2023 | Volume 22 | Issue 4 | Original Article | 333 | Copyright © April 2023

Background: Dyschromia can be caused by abnormalities in the increased production and/or reduced clearance of pigmentation in the skin. Causes of hyperpigmentation include excessive s...
Read More

The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study

February 2023 | Volume 22 | Issue 2 | Original Article | 139 | Copyright © February 2023

Background: Patients with atopic dermatitis (AD) need safe and effective topical treatments.
Objective: To assess safety and efficacy of roflumilast cream in pa...
Read More

Efficacy and Safety of Calcipotriene/Betamethasone Dipropionate Foam in the Treatment of Psoriasis in Skin of Color

February 2023 | Volume 22 | Issue 2 | Original Article | 165 | Copyright © February 2023

Background: There is a paucity of data on usage of topical medications in patients with darker phototypes. This single-center, randomized, double-blinded, vehicle-controlled clinical ...
Read More

Efficacy and Safety of 1% Clascoterone Cream in Patients Aged > 12 Years With Acne Vulgaris

February 2023 | Volume 22 | Issue 2 | Original Article | 174 | Copyright © February 2023

A Prospective 2-Year Extension Study to Evaluate the Safety and Effectiveness of PMMA-collagen Gel for the Correction of Mid-Facial Volume Loss

January 2023 | Volume 22 | Issue 1 | Original Article | 60 | Copyright © January 2023

Background: The safety and efficacy of polymethylmethacrylate (PMMA)-collagen gel for long-lasting correction of mid-face volume deficit was established for 12 months.
O...
Read More

JAK Inhibitor Safety Compared to Traditional Systemic Immunosuppressive Therapies

December 2022 | Volume 21 | Issue 12 | Original Article | 1298 | Copyright © December 2022

Dermatologists treating atopic dermatitis are interested in the safety profile of the recently available JAK inhibitors, upadacitinib and abrocitinib, especially after they received boxed safety warni...
Read More

Dermal Safety of Tapinarof Cream 1%: Results From 4 Phase 1 Trials

October 2022 | Volume 21 | Issue 10 | Original Article | 1084 | Copyright © October 2022

Background: Tapinarof (VTAMA^®; Dermavant Sciences, Inc.) is a novel, non-steroidal, topical, aryl hydrocarbon receptor agonist, FDA approved for psoriasis treatment and...
Read More